Research Network Awarded $15 Million to Study Heart Valve Disease

The program is designed to advance understanding of how to diagnose and treat heart valve disease earlier and more effectively.

Each center will host collaborative projects, bringing together multidisciplinary teams to address knowledge gaps in valvular disease.

The current effort adds to 19 networks previously funded by the Association and to the total investment exceeding $6.1 billion in cardiovascular, cerebrovascular, and brain health research since 1949.

• The American Heart Association (AHA) has launched a four-year, $15 million initiative, the Strategically Focused Research Network on Earlier Detection and Delaying Progression of Valvular Heart Disease.
• Leadership and centers: Investigative leadership will be distributed across three funded centers—Mass General Brigham Heart and Vascular Institute (Boston), Cincinnati Children’s Hospital Center, and the University of Pittsburgh.
• Foundation context: The AHA notes that this new network is part of a broader portfolio of Strategically Focused Research Networks established to tackle high-priority areas in cardiovascular health.

In the United States, valvular disease contributes to a sizeable number of deaths annually.

If left untreated, such disease can progress to heart failure, arrhythmia, more frequent hospitalizations, diminished quality of life, and increased mortality.

Early detection and diagnosis before symptom onset may expand treatment options and potentially mitigate complications and quality-of-life degradation.

• Scope of disease: There is a substantial global burden of heart valve disease, with more than 80 million people living with some form of valvular condition worldwide at the time of the report.
• Pathophysiology overview stated in the source: Heart valve disease involves impairment of one or more of the heart’s four valves, leading to restricted blood flow or insufficient closure that results in backward blood flow.
• Symptomatology and screening emphasis: The report highlights that valvular disease often progresses without clear symptoms and tends to become more common with advancing age.

• Strategic emphasis: The initiative emphasizes earlier detection and prevention of progression in valvular heart disease, reflecting a focus on identifying preclinical or early-stage disease markers and understanding mechanisms that may slow or alter disease trajectories.
• Alignment with clinical priorities: The program aligns with AHA’s identified focus areas and ongoing efforts to improve patient care through quality improvement programs and targeted initiatives related to valvular heart disease, including educational and system-level improvements.

The goal is to explore new diagnostic approaches, preventive strategies, and therapeutic avenues that could alter disease progression.

• Network structure: The initiative comprises three to six centers within each network, incorporating investigators across basic, clinical, and population/behavioral health science domains.
• Collaborative scope: Projects are designed to be cross-center and collaborative, enabling integration of diverse expertise to address core questions about early detection, diagnostic advancements, and progression delay in valvular disease.
• Timeframe and initiation: The four-year award cycle commenced on April 1, 2026, with ongoing collaboration among centers beginning at that time.

Rosen, M.D., FAHA, who serves as volunteer president of the AHA and holds leadership roles in health institutions in New York City, and who provided commentary framing the initiative and its significance.

Hilaire, Ph.D., FAHA, director of the Center for Integrative Valve Science and associate professor of medicine at the University of Pittsburgh

• Principal contributors include: Stacey E.
• Center leadership and representatives:
• Mass General Brigham Heart and Vascular Institute in Boston (noted as a center of leadership)
• Cincinnati Children’s Hospital Medical Center (pediatric cardiology leadership)
• University of Pittsburgh (Center for Integrative Valve Science)
• Individual project leads named in the source include:
• Andrea Beaton, M.D., M.S., FAHA, professor of pediatrics at the University of Cincinnati and pediatric cardiologist at Cincinnati Children’s Hospital Medical Center
• Elena Aikawa, M.D., Ph.D., FAHA, director of the Heart Valve Translational Research Program at Brigham and Women’s
• Cynthia St.

The new valve-focused network sits within this broader ecosystem and aims to contribute to diagnostic and therapeutic advances in valvular disease.

The association frames its work as advancing discovery and applying findings to real-world care, policy, and health systems.

• Prior and ongoing research networks: The AHA notes a history of extensive investment in research networks addressing broad topics relevant to cardiovascular and cerebrovascular health, including prevention, hypertension, women's health, heart failure, obesity, vascular disease, atrial fibrillation, arrhythmias, cardiometabolic disease, health technology, cardio-oncology, psychosocial stress, inflammation in cardiovascular health, and cardio-kidney-metabolic syndrome.
• Purpose and mission: The AHA describes its funding approach as central to advancing lifesaving science in cardiovascular and brain health, aiming to translate new knowledge into improved patient outcomes.

• Burden data cited: The source references the AHA 2026 Heart Disease and Stroke Statistics to quantify the prevalence and mortality burden of heart valve disease, noting substantial numbers both globally and in the United States.
• Quality and trust considerations: The AHA and associated initiatives are presented within a framework of public health communication, with reference to trust in health information and the organization’s role as a leader in disseminating evidence-based health information.

However, the source does not provide specific results, metrics, or measured outcomes from the new network since the program is at its inception.

• Potential outcomes highlighted by the report include earlier detection, better diagnostic capabilities, and delayed progression of valvular disease, with the expectation that these advances could expand treatment options and reduce adverse outcomes.
• Practical relevance: The initiative is positioned as a platform to generate new knowledge that could influence clinical practice patterns, health system workflows, and patient care pathways related to valvular disease, consistent with the AHA’s broader institutional goals.

It does not present preliminary results, specific trial designs, patient populations, inclusion criteria, or exact project plans beyond the general collaborative framework.

• Reporting caveats: The source is a descriptive announcement detailing the initiation, funding, centers, and leadership.